Oral small molecule GLP-1 receptor agonist
HRS-7535 120 mg tablet once daily
HRS7535_PO_120MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -2.59 (-13.51 to 8.26) | 0.42 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -3.51 (-9.61 to 3.53) | 0.29 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -3.49 (-10.13 to 3.82) | 0.25 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.15 (0.00 to 2.78) | 0.83 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.25 (0.00 to 6.22) | 0.81 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.64 (2.73 to 26.62) | 0.20 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 9.86 (3.03 to 42.11) | 0.22 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.92 (0.94 to 9.64) | 0.33 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.39 (0.39 to 49.17) | 0.29 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.42 (0.01 to 16.06) | 0.72 |